Company: REVB
Filing Date: 2025-01-21
Form Type: 8-K
Source: 0000950170-25-007303
Chunk: 3

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-01-21
Form: 8-K
Item: Item 8.01
Chunk 3
---
Item 8.01 Other Events.

On January 21, 2025, the Company issued a press release titled “ Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information in Item 8.01 and in Exhibit 99.1 will not be treated as “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or otherwise subject to the liabilities of that section. This information will not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or into another filing under the Exchange Act, unless that filing expressly incorporates this information by reference.

Item 9.01 Financial Statements and Exhibits.